Company research
Eledon Pharmaceuticals, Inc.
CIK 1404281Updated Nov 13, 2026
SecurityELDN · NASDAQ · equity
Name history
Eledon Pharmaceuticals, Inc. · through Nov 12, 2026Novus Therapeutics, Inc. · through Dec 22, 2020Tokai Pharmaceuticals Inc · through May 4, 2017
ELDN price & chart
Loading TradingView…
NASDAQ:ELDN on TradingView ↗About the company
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40L biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, liver transplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.
In the news
Seeking Alpha
Eledon Pharmaceuticals GAAP EPS of -$0.03 beats by $0.14 ↗
NewcelX prices $1.55M share offering at $3.29 to fund diabetes program ↗
Eledon Pharmaceuticals, Inc. (ELDN) Presents at International Congress of The Transplantation Society 2026 - Slideshow ↗
SEC disclosures
Eledon Pharmaceuticals, Inc. files 8-K: Material Event ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
S-8 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
SCHEDULE 13G - filed by VANGUARD CAPITAL MANAGEMENT LLC regarding Eledon Pharmaceuticals, Inc.
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security Holders
Items 5.03, 5.07, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
EFFECT filing
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 129,857,000Source | 114,576,000Source | 126,094,000Source | 144,909,000Source | 120,483,000Source | 146,667,000Source | 161,308,000Source | 80,818,000Source | 169,009,000Source | 177,405,000Source | — | 92,793,000Source |
| GoodwillUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 3,669,000Source | 6,751,000Source | 6,803,000Source | 5,741,000Source | 26,039,000Source | 6,152,000Source | 8,496,000Source | 5,655,000Source | 22,808,000Source | 20,549,000Source | — | 56,409,000Source |
| Assets, CurrentUSD | 96,301,000Source | 81,509,000Source | 93,091,000Source | 111,404,000Source | 87,221,000Source | 113,574,000Source | 127,718,000Source | 47,977,000Source | 135,688,000Source | 143,730,000Source | — | 59,518,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,900,000Source | 3,318,000Source | 4,335,000Source | 3,834,000Source | 3,611,000Source | 2,485,000Source | 2,837,000Source | 5,115,000Source | 2,352,000Source | 3,552,000Source | — | 3,109,000Source |
| Operating Lease, Right-of-Use AssetUSD | 694,000Source | 471,000Source | 445,000Source | 773,000Source | 621,000Source | 530,000Source | 850,000Source | 270,000Source | 613,000Source | 926,000Source | — | 739,000Source |
| Other Assets, NoncurrentUSD | 476,000Source | 210,000Source | 172,000Source | 346,000Source | 255,000Source | 177,000Source | 354,000Source | 185,000Source | 322,000Source | 363,000Source | — | 150,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 38,803,000Source | 38,518,000Source | 54,063,000Source | 38,881,000Source | 128,984,000Source | 46,209,000Source | 46,728,000Source | 95,546,000Source | 32,230,000Source | 59,265,000Source | 63,017,000Source | 8,610,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 60,000Source | 41,000Source | 81,000Source | 60,000Source | 39,000Source | 76,000Source | 60,000Source | 25,000Source | 75,000Source | 60,000Source | 23,000Source | 14,000Source |
| Retained Earnings (Accumulated Deficit)USD | -390,756,000Source | -310,969,000Source | -471,858,000Source | -373,297,000Source | -387,940,000Source | -440,228,000Source | -362,081,000Source | -343,033,000Source | -401,203,000Source | -355,586,000Source | -279,397,000Source | -202,865,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 9,000Source | 102,000Source | -114,000Source | -48,000Source | — | -72,000Source | -18,000Source | — | 24,000Source | 26,000Source | — | — |
| Stockholders' Equity Attributable to ParentUSD | 35,360,000Source | 20,364,000Source | 33,013,000Source | 50,334,000Source | -64,195,000Source | 44,764,000Source | 58,886,000Source | -70,422,000Source | 81,085,000Source | 62,446,000Source | 43,768,000Source | 84,183,000Source |
| Additional Paid in Capital, Common StockUSD | 426,047,000Source | 331,190,000Source | 504,904,000Source | 423,619,000Source | 323,706,000Source | 484,988,000Source | 420,925,000Source | 328,280,000Source | 482,189,000Source | 417,946,000Source | 323,142,000Source | 287,034,000Source |
| Liabilities and EquityUSD | 129,857,000Source | 114,576,000Source | 126,094,000Source | 144,909,000Source | 120,483,000Source | 146,667,000Source | 161,308,000Source | 80,818,000Source | 169,009,000Source | 177,405,000Source | — | 92,793,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 14,296,000Source | 12,489,000Source | 11,789,000Source | 13,719,000Source | 6,025,000Source | 13,458,000Source | 9,185,000Source | 4,247,000Source | 18,344,000Source | 11,577,000Source | — | 6,475,000Source |
| Operating Lease, Liability, CurrentUSD | 346,000Source | 186,000Source | 381,000Source | 336,000Source | 269,000Source | 369,000Source | 325,000Source | 284,000Source | 358,000Source | 314,000Source | — | 363,000Source |
| Accounts Payable, CurrentUSD | 4,627,000Source | 5,860,000Source | 3,214,000Source | 5,831,000Source | 2,148,000Source | 6,585,000Source | 2,901,000Source | 1,864,000Source | 3,627,000Source | 5,833,000Source | — | 2,200,000Source |
| Operating Lease, Liability, NoncurrentUSD | 376,000Source | 315,000Source | 86,000Source | 467,000Source | 386,000Source | 186,000Source | 555,000Source | 0Source | 283,000Source | 640,000Source | — | 383,000Source |
| Deferred Income Tax Liabilities, NetUSD | 2,183,000Source | 1,752,000Source | 2,187,000Source | 2,183,000Source | 1,752,000Source | 2,187,000Source | 2,183,000Source | 1,752,000Source | 2,187,000Source | 2,183,000Source | — | 1,752,000Source |
| Additional Financial Items | ||||||||||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 93,400,000Source | 78,200,000Source | 88,800,000Source | 107,600,000Source | 83,600,000Source | 111,100,000Source | 124,900,000Source | 42,900,000Source | 133,300,000Source | — | — | — |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 2,187,000Source | 2,183,000Source | — | 1,752,000Source |
| Short-term InvestmentsUSD | 89,732,000Source | 71,440,000Source | 81,953,000Source | 101,829,000Source | 57,571,000Source | 104,937,000Source | 116,385,000Source | 37,207,000Source | 110,528,000Source | 119,629,000Source | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 5,000Source | 431,000Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -22,612,000Source | -16,060,000Source | -62,341,000Source | -47,271,000Source | -39,527,000Source | -28,424,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 5,956,000Source | 3,892,000Source | 10,793,000Source | -70,314,000Source | -45,287,000Source | — |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | 115,000Source | 53,807,000Source | 133,522,000Source | 33,017,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -16,656,000Source | -12,053,000Source | 2,259,000Source | 15,937,000Source | -51,797,000Source | -28,424,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 3,669,000Source | 6,751,000Source | 6,803,000Source | 5,741,000Source | 6,152,000Source | 8,496,000Source | 22,808,000Source | 20,549,000Source | 4,612,000Source | 56,409,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 28,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 2,428,000Source | 1,783,000Source | 3,154,000Source | 2,694,000Source | 2,202,000Source | 2,864,000Source | 10,451,000Source | 13,122,000Source | 6,545,000Source | 8,153,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 93,400,000Source | 78,200,000Source | 88,800,000Source | 107,600,000Source | 111,100,000Source | 124,900,000Source | 133,300,000Source | — | 51,100,000Source | — |
| Gain (Loss) on Termination of LeaseUSD | — | — | — | — | — | — | — | — | — | 10,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 4,101,000Source | 3,990,000Source | 4,639,000Source | 4,457,000Source | 3,984,000Source | 4,433,000Source | 16,984,000Source | 18,613,000Source | 12,688,000Source | 12,700,000Source |
| GoodwillUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 48,648,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 35,000Source | 431,000Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -17,459,000Source | 76,971,000Source | -31,630,000Source | -11,216,000Source | -39,025,000Source | -6,495,000Source | -45,617,000Source | -36,184,000Source | -116,537,000Source | -87,966,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -16,130,000Source | 54,429,000Source | -30,242,000Source | -10,362,000Source | -36,935,000Source | -6,000,000Source | -42,328,000Source | — | — | — |
| Operating ExpensesUSD | — | — | 19,070,000Source | 20,510,000Source | 22,869,000Source | 24,733,000Source | 21,181,000Source | 17,964,000Source | 83,251,000Source | 70,577,000Source | 43,000,000Source | 88,428,000Source |
| Operating Lease, ExpenseUSD | — | — | 100,000Source | 100,000Source | 100,000Source | 100,000Source | 100,000Source | 100,000Source | 400,000Source | 400,000Source | 400,000Source | 300,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 1,047,000Source | 1,042,000Source | 862,000Source | 1,224,000Source | 1,118,000Source | 1,409,000Source | 4,220,000Source | 3,924,000Source | 2,674,000Source | 462,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | 115,000Source | 230,000Source | 215,000Source | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -19,070,000Source | -20,510,000Source | -22,869,000Source | -24,733,000Source | -21,181,000Source | -17,964,000Source | — | — | -43,000,000Source | -88,428,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 1,047,000Source | 1,042,000Source | 862,000Source | 1,224,000Source | 1,118,000Source | 1,409,000Source | 4,220,000Source | 3,924,000Source | 2,674,000Source | 462,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -45,582,000Source | -35,753,000Source | -116,537,000Source | -87,966,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 35,000Source | 431,000Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -17,459,000Source | 76,971,000Source | -31,630,000Source | -11,216,000Source | -39,025,000Source | -6,495,000Source | -45,617,000Source | -36,184,000Source | -116,537,000Source | -87,966,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.21Source | 1.05Source | -0.27Source | -0.13Source | -0.33Source | -0.08Source | -0.52Source | -0.75Source | -4.73Source | -6.16Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.21Source | -0.28Source | -0.27Source | -0.13Source | -0.33Source | -0.08Source | -0.52Source | -0.75Source | -4.73Source | -6.16Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 77,156,068Source | 51,945,920Source | 113,631,565Source | 77,156,068Source | 112,424,211Source | 77,126,763Source | 81,836,246Source | 48,543,787Source | 24,619,197Source | 14,285,254Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 77,156,068Source | 55,478,342Source | 113,631,565Source | 77,156,068Source | 112,424,211Source | 77,126,763Source | 81,836,246Source | 48,543,787Source | 24,619,197Source | 14,285,254Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 30,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 4,101,000Source | 3,990,000Source | 4,639,000Source | 4,457,000Source | 3,984,000Source | 4,433,000Source | 16,984,000Source | 18,613,000Source | 12,688,000Source | 12,700,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 48,648,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -45,781,000Source | -35,951,000Source | -116,736,000Source | -88,159,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -16,130,000Source | 54,429,000Source | -30,242,000Source | -10,362,000Source | -36,935,000Source | -6,000,000Source | -42,328,000Source | — | — | — |
| Operating ExpensesUSD | — | — | 19,070,000Source | 20,510,000Source | 22,869,000Source | 24,733,000Source | 21,181,000Source | 17,964,000Source | 83,251,000Source | 70,577,000Source | 43,000,000Source | 88,428,000Source |
| Operating Lease, ExpenseUSD | — | — | 100,000Source | 100,000Source | 100,000Source | 100,000Source | 100,000Source | 100,000Source | 400,000Source | 400,000Source | 400,000Source | 300,000Source |
| Research and Development ExpenseUSD | — | — | 14,969,000Source | 16,520,000Source | 18,230,000Source | 20,276,000Source | 17,197,000Source | 13,531,000Source | 66,267,000Source | 51,964,000Source | 30,312,000Source | 27,080,000Source |
| Undistributed Earnings (Loss) Allocated to Participating Securities, Basic | — | — | — | —Source | — | — | — | — | — | — | — | — |
Offerings
Registration 333-295498
Filing attachments
eldn-ex99_1.htm · 8-K · 2026-11-12
Exhibit 99.1 Eledon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Business Highlights Planned global Phase 3 LEGACY trial of tegoprubart in kidney transplantation remains on track to initiate in Q4 2026 FDA cleared the Company’s IND application for a planned registrational path study of tegoprubart in islet cell transplantation for patients with type 1 diabetes FDA Fast Track designation granted to tegoprubart for the prevention of rejection in kidney transplantatio…
Read attachment ↗d167098dex42.htm · S-8 · 2026-09-04
Exhibit 4.2 ELEDON PHARMACEUTICALS, INC. NON-QUALIFIED STOCK OPTION INDUCEMENT AWARD AGREEMENT GRANT OF OPTION. This agreement evidences the grant by ELEDON PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), on [ ] (the “Grant Date”) to [ ], an employee of the Company (the “Participant”), and is made in connection with Participant’s entry into that certain employment agreement with the Company dated as of [ ] (the “Employment Agreement”) and is an inducement material to t…
Read attachment ↗eldn-ex99_1.htm · 8-K · 2026-08-13
EX-99.1 2 eldn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights Successful End-of-Phase 2 meeting with FDA supports advancement of tegoprubart into a global Phase 3 kidney transplantation trial, on track to initiate in late 2026 Long-term Phase 2 BESTOW data presented at ATC 2026 demonstrated sustained higher kidney function and improved patient-reported outcomes with tegoprubart compared with tacr…
Read attachment ↗eldn-ex99_1.htm · 8-K · 2026-05-13
EX-99.1 2 eldn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights 100% insulin independence achieved in 10 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study FDA Orphan Drug designation granted to tegoprubart for the prevention of allograft rejection in liver transplantation Cash, cash equivalents and short-term investments totaled $1…
Read attachment ↗d79008dex412.htm · S-3 · 2026-05-01
Exhibit 4.12 ELEDON PHARMACEUTICALS, INC. INDENTURE Dated as of, 20 [ ] Trustee Senior Debt Securities TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions …
Read attachment ↗d79008dex413.htm · S-3 · 2026-05-01
Exhibit 4.13 ELEDON PHARMACEUTICALS, INC. INDENTURE Dated as of, 20 [ ] Trustee Subordinated Securities TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions …
Read attachment ↗